Objective:

To investigate the effectiveness of a Flavo-Proxylane skincare regimen combined with ultrasound treatment in mitigating specific dermatologic changes, such as skin laxity and volume loss, in patients using GLP-1 receptor agonists.

Key Findings:

• Flavo-Proxylane treatment resulted in significant improvements in facial skin laxity and marionette lines compared to baseline and placebo, highlighting its effectiveness.
• 64% of participants reported moderate-to-significant overall aesthetic improvement with Flavo-Proxylane treatment compared to placebo, indicating a strong preference for this regimen.
• Both Flavo-Proxylane and placebo treatments were well tolerated, with substantial improvements in clinical grading parameters, although no significant between-group differences were noted.

Interpretation:

The Flavo-Proxylane regimen, when combined with ultrasound, may provide synergistic benefits for skin health in GLP-1 RA users, addressing aesthetic concerns associated with these medications and suggesting a new avenue for dermatologic care.

Limitations:

• Further longitudinal research is needed to fully understand the synergistic potential and patient-level factors influencing efficacy, including age, skin type, and duration of GLP-1 RA use.
• The study's sample size and duration may limit the generalizability of the findings, necessitating larger trials to confirm results.

Conclusion:

A targeted Flavo-Proxylane skincare protocol appears effective in improving dermatologic outcomes for patients on GLP-1 RA therapy, warranting further investigation into its long-term effects and potential integration into standard care practices.